Surgery for mesothelioma

Prof dr Paul Van Schil, thoracic surgeon from Antwerp University Hospital and the new president of IASLC, took the time for an interview about the role of surgery for mesothelioma. He dives into the results of the EORTC 1205 study, a randomised phase II study of surgery for mesothelioma preceded or followed by chemotherapy, but also discusses the outcomes of the MARS 2 trial where there seemed to be no benefit for surgery on top of chemotherapy in mesothelioma patients. As the new president of IASLC, Prof Dr Van Schil also shares his vision on the ambition of the association within the coming years.

With the educational support of: